CN104382905A - 羧胺三唑(cai)乳清酸盐在黄斑变性中的用途 - Google Patents

羧胺三唑(cai)乳清酸盐在黄斑变性中的用途 Download PDF

Info

Publication number
CN104382905A
CN104382905A CN201410584804.0A CN201410584804A CN104382905A CN 104382905 A CN104382905 A CN 104382905A CN 201410584804 A CN201410584804 A CN 201410584804A CN 104382905 A CN104382905 A CN 104382905A
Authority
CN
China
Prior art keywords
angiogenesis
cai
disease
orotate
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410584804.0A
Other languages
English (en)
Chinese (zh)
Inventor
拉希达·A·卡马利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KARMALI RASHIDA Co
Tactical Therapeutics Inc
Original Assignee
KARMALI RASHIDA Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39492872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104382905(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by KARMALI RASHIDA Co filed Critical KARMALI RASHIDA Co
Publication of CN104382905A publication Critical patent/CN104382905A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201410584804.0A 2006-12-06 2007-12-05 羧胺三唑(cai)乳清酸盐在黄斑变性中的用途 Pending CN104382905A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/634,422 US7750018B2 (en) 2006-12-06 2006-12-06 Use of carboxiamidotriazole (CAI) orotate in macular degeneration
US11/634,422 2006-12-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800454661A Division CN101578099A (zh) 2006-12-06 2007-12-05 羧胺三唑(cai)乳清酸盐在黄斑变性中的用途

Publications (1)

Publication Number Publication Date
CN104382905A true CN104382905A (zh) 2015-03-04

Family

ID=39492872

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201410584804.0A Pending CN104382905A (zh) 2006-12-06 2007-12-05 羧胺三唑(cai)乳清酸盐在黄斑变性中的用途
CN2013100054685A Pending CN103251601A (zh) 2006-12-06 2007-12-05 羧胺三唑(cai)乳清酸盐在黄斑变性中的用途
CNA2007800454661A Pending CN101578099A (zh) 2006-12-06 2007-12-05 羧胺三唑(cai)乳清酸盐在黄斑变性中的用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN2013100054685A Pending CN103251601A (zh) 2006-12-06 2007-12-05 羧胺三唑(cai)乳清酸盐在黄斑变性中的用途
CNA2007800454661A Pending CN101578099A (zh) 2006-12-06 2007-12-05 羧胺三唑(cai)乳清酸盐在黄斑变性中的用途

Country Status (10)

Country Link
US (2) US7750018B2 (fr)
EP (1) EP2089021B1 (fr)
JP (1) JP5344764B2 (fr)
KR (1) KR101414922B1 (fr)
CN (3) CN104382905A (fr)
AU (1) AU2007328027B2 (fr)
CA (1) CA2682596C (fr)
ES (1) ES2488093T3 (fr)
IL (1) IL199158A (fr)
WO (1) WO2008070169A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877785B2 (en) * 2009-09-04 2014-11-04 Tactical Therapeutics Inc Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
US9089570B2 (en) * 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
US10378059B2 (en) * 2013-08-02 2019-08-13 Tactical Therapeutics, Inc. Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
KR101796684B1 (ko) 2016-05-19 2017-11-10 건국대학교 산학협력단 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법
CN111253327A (zh) * 2018-12-03 2020-06-09 中国医学科学院基础医学研究所 羧胺三唑类化合物或其盐在制备治疗nlrp3炎症小体活化相关疾病的药物中的应用
CN111249277A (zh) * 2018-12-03 2020-06-09 中国医学科学院基础医学研究所 羧胺三唑类化合物在制备治疗或预防自身炎症性疾病的药物中的应用
EP4079309A4 (fr) * 2019-12-16 2024-01-10 Ulsan National Institute Of Science And Tech Unist Composé destiné à inhiber le facteur d'angiogenèse et son utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037106A2 (fr) * 2004-09-24 2006-04-06 Rfe Pharma Llc Systemes bases sur cai et methodes de traitement localise de maladies oculaires et autres

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
US5196522A (en) * 1990-11-01 1993-03-23 Board Of Regents, The University Of Texas System Anthracycline analogues bearing latent alkylating substituents
US5744492A (en) 1993-09-17 1998-04-28 United States Of America Method for inhibiting angiogenesis
ES2072223B1 (es) * 1993-11-25 1996-03-16 Lipotec Sa Liposomas encapsulando doxorubicina.
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
ATE278399T1 (de) * 1995-07-21 2004-10-15 Savvipharm Inc Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
US6210930B1 (en) * 1997-03-06 2001-04-03 Pharmacia & Upjohn, S.P.A. Process for preparing doxorubicin
IL138572A0 (en) * 1998-03-25 2001-10-31 Biosource Genetics Corp Benzoate derivatives and pharmaceutical compositions containing the same
DE69922681T2 (de) * 1998-10-16 2005-05-25 Mercian Corp. Kristallisation von doxorubicin-hydrochlorid
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
AU2003296085A1 (en) * 2002-12-24 2004-07-22 Nitto Boseki Co., Ltd. Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037106A2 (fr) * 2004-09-24 2006-04-06 Rfe Pharma Llc Systemes bases sur cai et methodes de traitement localise de maladies oculaires et autres

Also Published As

Publication number Publication date
CN101578099A (zh) 2009-11-11
EP2089021A2 (fr) 2009-08-19
US7750018B2 (en) 2010-07-06
AU2007328027B2 (en) 2012-11-15
JP2010512318A (ja) 2010-04-22
US8420658B2 (en) 2013-04-16
CA2682596C (fr) 2014-03-18
IL199158A (en) 2014-07-31
US20080139592A1 (en) 2008-06-12
KR101414922B1 (ko) 2014-07-04
US20100298363A1 (en) 2010-11-25
EP2089021B1 (fr) 2014-06-04
EP2089021A4 (fr) 2009-12-30
JP5344764B2 (ja) 2013-11-20
AU2007328027A2 (en) 2010-07-08
CN103251601A (zh) 2013-08-21
AU2007328027A1 (en) 2008-06-12
CA2682596A1 (fr) 2008-06-12
WO2008070169A3 (fr) 2008-11-06
ES2488093T3 (es) 2014-08-26
WO2008070169A2 (fr) 2008-06-12
KR20090096442A (ko) 2009-09-10

Similar Documents

Publication Publication Date Title
CN104382905A (zh) 羧胺三唑(cai)乳清酸盐在黄斑变性中的用途
US20110046119A1 (en) Therapeutic treatment
AU2005275023A1 (en) Compositions and methods for treatment of colitis
US5622994A (en) Spin trapping pharmaceutical compositions and methods for use thereof
KR20060024343A (ko) 귀금속 미립자를 함유하는 의약
JP4609877B2 (ja) 慢性拒絶反応抑制剤
AU2008201290B2 (en) Therapeutic treatment
JPS59157021A (ja) 動脈硬化症予防治療剤
CA2684171C (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
JP3845307B2 (ja) 心筋梗塞治療薬
WO2021142020A1 (fr) Formulations de sn-38 avec des polymères séquencés de poly(acide aminé)
JP2002515905A (ja) 肝硬変の治療

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150304

RJ01 Rejection of invention patent application after publication